SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2382Why REGN/SNY can not do something like this???? clinicaltrials.gov (BGNE-PD1 hmMiljenko Zuanic-4/10/2018
2381This would be nice addition to Kevzara, but they are so SLOW: medpagetoday.com Miljenko Zuanic-4/7/2018
2380They need break true with additional drug (like Eylea), but not splitting US-shaMiljenko Zuanic14/7/2018
2379I think the company is fine just that the stock price will be stagnant for some Felix B-4/7/2018
2378< It would have to be something huge and unexpected like large Kevzara or PraMiljenko Zuanic-4/7/2018
2377At this point, I don't think anything will move the needle. It would have tFelix B-4/7/2018
2376RE: Dupi 1Q US sale Based on TRx/BNRx numbers, I am projecting 1Q sale at ~$175Miljenko Zuanic14/6/2018
2375Must be severity, look at Soliris and they get no pushback. Then again humira hFelix B-4/6/2018
2374Continuation of the same story in EU, starting with UK: fiercepharma.com Is it Miljenko Zuanic-4/3/2018
2373One way or another, it will not be "overnight" development.Miljenko Zuanic-4/2/2018
2372I mean any of their external collaborations (Decibel, ANLY, etc), curious what wFelix B-4/1/2018
2371Happy Easter to all, who celebrate. No, as far as I know. It is platform collabMiljenko Zuanic-4/1/2018
2370Thanks for sharing. Curious if any of the recent external collaborations pan ouFelix B-3/31/2018
2369Yan in Nature Reviews: readcube.comMiljenko Zuanic13/30/2018
2368One simple comment on today ESPR's BA result in P2: After well(???) executeMiljenko Zuanic-3/27/2018
2367Chiron patent is from 1984!Miljenko Zuanic-3/24/2018
2366NVS has nothing to lose by trying, other than some modest legal expenses.DewDiligence_on_SI-3/24/2018
2365Very desperate.Felix B-3/24/2018
2364Desperate action by Novartis, lifesciencesipreview.comMiljenko Zuanic-3/23/2018
2363Dupi continue with "troubled" trajectory. Market penetration is slow, Miljenko Zuanic-3/23/2018
2362Yes, it was. They only validated target, by confirming LofF mutation outcome. OtMiljenko Zuanic-3/22/2018
2361This was already known as a NASH target. Zhu Y, Imperato-McGinley JL (9 NovemBiotech Jim-3/21/2018
2360I think that siRNA GalNAc-conjugate approach from ALNY is good choice for liver Miljenko Zuanic-3/21/2018
2359RGC finally got their target although unexpected partner: investor.regeneron.coFelix B-3/21/2018
2358I've always wondered how much sway these analysts have. Although a majorityFelix B-3/19/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News